2.50
Hdl Handle:
http://hdl.handle.net/10541/75665
Title:
Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis.
Authors:
Lau, Sin C; Rosa, Daniela D; Jayson, Gordon C ( 0000-0002-8515-8944 )
Abstract:
sanofi-aventis (formerly Aventis) and Regeneron are developing systemic VEGF Trap, a soluble decoy receptor comprising portions of VEGF receptors 1 and 2, for the potential intravenous/subcutaneous treatment of cancer.
Affiliation:
Cancer Research UK, Department of Medical Oncology, Christie Hospital, Withington, Manchester, UK.
Citation:
Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis. 2005, 7 (5):493-501 Curr. Opin. Mol. Ther.
Journal:
Current Opinion in Molecular Therapeutics
Issue Date:
Oct-2005
URI:
http://hdl.handle.net/10541/75665
PubMed ID:
16248285
Type:
Article
Language:
en
ISSN:
1464-8431
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorLau, Sin C-
dc.contributor.authorRosa, Daniela D-
dc.contributor.authorJayson, Gordon C-
dc.date.accessioned2009-07-24T15:40:45Z-
dc.date.available2009-07-24T15:40:45Z-
dc.date.issued2005-10-
dc.identifier.citationTechnology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis. 2005, 7 (5):493-501 Curr. Opin. Mol. Ther.en
dc.identifier.issn1464-8431-
dc.identifier.pmid16248285-
dc.identifier.urihttp://hdl.handle.net/10541/75665-
dc.description.abstractsanofi-aventis (formerly Aventis) and Regeneron are developing systemic VEGF Trap, a soluble decoy receptor comprising portions of VEGF receptors 1 and 2, for the potential intravenous/subcutaneous treatment of cancer.en
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAngiogenesis Inhibitors-
dc.subject.meshAnimals-
dc.subject.meshClinical Trials, Phase I as Topic-
dc.subject.meshDrug Evaluation, Preclinical-
dc.subject.meshHumans-
dc.subject.meshMice-
dc.subject.meshNeoplasms-
dc.subject.meshVascular Endothelial Growth Factor A-
dc.subject.meshVascular Endothelial Growth Factor Receptor-1-
dc.subject.meshVascular Endothelial Growth Factor Receptor-2-
dc.titleTechnology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK, Department of Medical Oncology, Christie Hospital, Withington, Manchester, UK.en
dc.identifier.journalCurrent Opinion in Molecular Therapeuticsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.